Livedoid vasculitis - Ливедоидни Васкулитис
Ливедоидни Васкулитис (Livedoid vasculitis) је хронична кожна болест која се најчешће јавља код млађих и средовешних жена. Један акроним који се користи за описивање његових карактеристика је „Болни пурпурни улкуси са ретикуларним узорком доњих екстремитета“ (ПУРПЛЕ). Повезан је са бројним болестима, укључујући хроничну венску хипертензију и варикозитет.
☆ AI Dermatology — Free Service
У резултатима Стифтунг Варентест-а за 2022. из Немачке, задовољство потрошача МоделДерм-ом је само нешто ниже него са плаћеним телемедицинским консултацијама.
У резултатима Стифтунг Варентест-а за 2022. из Немачке, задовољство потрошача МоделДерм-ом је само нешто ниже него са плаћеним телемедицинским консултацијама.
Може бити праћено болом.
relevance score : -100.0%
ReferencesLivedoid vasculopathy је ретко стање коже које карактерише појаву болних чирева који се стално враћају на потколенице.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy је ретко стање коже које изазива понављајуће чиреве на потколеницама, остављајући бледе ожиљке познате као атрофија бланш. Иако је тачан узрок још увек нејасан, сматра се да је повећано згрушавање крви (hypercoagulability) главни фактор, док упала игра споредну улогу. Фактори који доприносе згрушавању укључују: недостатак протеина C и S, генетске мутације као што је фактор V Leiden, недостатак антитромбина III, мутације гена протромбина и високе нивое хомоцистеина. У биопсијама се уочавају крвни угрушаци унутар судова, задебљање зидова судова и ожиљци. Лечење захтева вишеструки приступ који се фокусира на превенцију крвних угрушака лековима као што су антиагреганси, разређивачи крви и фибринолитичка терапија. За ово стање коже могу се користити различити лекови – colchicine и hydroxychloroquine, вазодилатори, имуносупресиви.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy је ретко стање у којем се лезије јављају на обе ноге. Сматра се да је стварање крвних угрушака у ситним крвним судовима узроковано повећаним згрушавањем и смањеном разградњом угрушка, уз оштећење слузнице крвних судова. Чешће се јавља код жена, посебно у узрасту од 15 до 50 година. Престанак пушења, збрињавање рана и употреба лекова као што су разређивачи крви и лекови против тромбоцита били су ефикасни.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
